Pharma Giant with $51.5 Billion Fortune Expands Ambitions with HK$2.8 Billion Acquisition

New Listing News | GenHouse Bio Submits Application to Hong Kong Stock Exchange

Meet the 90s-Born M&A Queen of China's Pharma Sector

IPO News | Immvira Bioscience Files for Hong Kong Listing

Outperforming Industry Index for 9 Consecutive Years: E Fund's Yang Zhenxiao's Dual-Engine Strategy to Navigate Pharmaceutical Cycles

Northeast Securities: Chinese Medical Device Companies Advance Up Global Value Chain, Domestic Market Returns to Steady Growth

At America's "Pharma Super Bowl," Chinese Biotechs Shift from "Optional" to "Essential"

CITIC SEC: AI Healthcare Commences Commercialization, Accelerating Reshaping of Trillion-Yuan Pharmaceutical Market

Qinhao Pharma Completes Over 300 Million Yuan Crossover Round Financing to Accelerate Sustained Innovation

Major Breakthrough: Abbisko-B's (02256) Tenosynovial Giant Cell Tumor Drug Bejema® NDA Accepted by FDA

HK Stock Movement | ALI HEALTH (00241) Rises Nearly 4%, Forms Strategic Partnership with Beijing Meiersen Pharmaceutical, Beimeijing® to Launch Exclusively Online This Tuesday

Tasly Darentang: Zhongxin Pharmaceutical No Longer Included in Consolidated Financial Statements

Hong Kong Market Movement | TYK MEDICINES-B (02410) Rises Over 4% in Afternoon Session; Mesylate Aidotinib Tablets (TY-9591 Tablets) Proposed for Priority Review

TYK MEDICINES-B (02410): TY-9591 Tablets Proposed for Priority Review

Healthcare Sector Rallies for Third Consecutive Session! Medical ETF Challenges Half-Year Moving Average, Hong Kong Stock Connect Innovative Drug ETF (520880) Surges Over 3% Against Market Trend! Multiple Brokerages Highlight Innovative Drug and Device Supply Chain

TYK MEDICINES-B (02410) Surges Over 10% as TY-9591 Tablets Designated for Priority Review

Nord Fund's Zhu Minglei Forecasts 2026 Investment Opportunities in Healthcare: Breakthrough and Renewal

Healthcare Management "Combination Punch" Boosts Public Well-being

Shiquan, Shaanxi Advances Quality Enhancement of Qinba Pharmaceutical Industry Chain

Caitong Securities: Leading Small Nucleic Acid Drug Firm Launches IPO, Sector Poised as Annual Healthcare Theme